Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-05-14 Capital/Financing Update
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Cleansing Statement 2 pages 202.4KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Statement issued by Nyrada Inc. regarding the issue of CHESS Depositary Interests (CDIs) related to a director placement. It references compliance with sections of the Corporations Act 2001 (Cth) and provides legal assurances about disclosure exemptions. The document is short (3339 characters) and primarily serves as a regulatory announcement about a capital issuance event rather than a detailed financial report or management discussion. It does not contain financial statements or detailed analysis but rather a formal notice about securities issuance and compliance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2025-05-14 English
Notification regarding unquoted securities - NYR 9 pages 29.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of new unquoted warrants to directors as approved at an Extraordinary General Meeting (EGM). It includes specifics about the securities issued, their terms, and references to the EGM notice. The content is focused on notifying the market about the issuance of new securities, specifically unquoted warrants, and the related approvals. This matches the description of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document is not a full financial report, earnings release, or management discussion, nor is it a proxy or voting result announcement. It is a formal notification of a capital change event.
2025-05-14 English
NYR-BI03 Extends Cardioprotection to Arrhythmia Control 5 pages 351.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Nyrada Inc. about the results of a preclinical study on their drug candidate NYR-BI03, focusing on cardioprotection and arrhythmia control. It includes scientific data, study results, biomarker analysis, and clinical trial updates. The content is primarily a scientific and clinical update rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or regulatory compliance information. It is not an annual or interim report, nor is it a call transcript or management discussion. The document is a corporate announcement of scientific study results and clinical trial progress, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2025-05-07 English
Phase I Clinical Trial Dosing Update No 2 3 pages 244.4KB
Regulatory Filings Classification · 95% confidence The document is a clinical trial update from Nyrada Inc. It provides detailed information about the progress of a Phase I clinical trial, including safety review committee findings, trial protocol details, and preclinical study results. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is an operational update on clinical trial progress rather than a financial report or regulatory filing. It is not an announcement of a report publication but a substantive update on clinical trial status. Therefore, it fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical trial progress that does not fit into other specific financial or corporate categories.
2025-05-01 English
Results of Meeting 4 pages 267.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Nyrada General Meeting Results' and provides detailed voting outcomes for resolutions passed at a General Meeting held on 17 April 2025. It includes proxy vote counts, percentages, and the final outcome of each resolution. The content focuses exclusively on the results of shareholder votes at a general meeting, referencing compliance with ASX Listing Rule 3.13.2 and Corporations Act Section 251AA(2). There is no financial data, management discussion, or other report content. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 6297 characters, sufficient to contain detailed voting results rather than a brief announcement. Therefore, the correct classification is DVA with high confidence.
2025-04-16 English
Quarterly Activities Report and Appendix 4C 9 pages 580.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and dated 15 April 2025. It contains detailed operational updates, clinical trial progress, patent application status, and a comprehensive Appendix 4C cash flow report for the quarter ended 31 March 2025. Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules (4.7B), which includes actual financial data such as cash flows from operating, investing, and financing activities, cash balances, and payments to related parties. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and operational updates for a quarter clearly identifies this as an Interim / Quarterly Report. It is not an earnings release (which would be shorter and focused on key financial highlights), nor a report publication announcement or regulatory filing. Therefore, the correct classification is Interim / Quarterly Report (IR).
2025-04-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.